Abstract
A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma
Journal of clinical oncology, Vol.44(2_suppl)
01/10/2026
DOI: 10.1200/JCO.2026.44.2_suppl.TPS273
Abstract
TPS273 Background: Ceramides and sphingosine-1-phosphate (S1P) are key bioactive signaling molecules. Ceramides are proapoptotic and mitigate chemoresistance. Conversely, S1P promotes cancer cell proliferation, activates multiple oncogenic pathways, and stimulates immuno-suppressor cell populations promoting a pro-tumoral microenvironment. Several studies in colorectal cancer patients have shown high levels of ceramides are associated with improved survival, while high S1P levels are associated with a poor prognosis. Hence, modulation of sphingolipid metabolism could be a promising therapeutic approach. BXQ-350 is a nanovesicle of Saposin C, an allosteric activator of sphingolipid metabolism, that lowers systemic S1P and increases C18 ceramide. BXQ-350 was investigated in a Phase 1 dose-escalation safety study in cancer patients with advanced solid malignancies (NCT02859857). BXQ-350 was safe and well-tolerated (no DLT, no MTD). Methods: BXQ-350 is being investigated in a Phase 1b/2 study in combination with mFOLFOX7 and Bevacizumab in newly diagnosed mCRC patients (NCT05322590) to assess the efficacy and safety of BXQ-350. Design of the Phase 1b (open label study): A safety dose escalation part to establish the RP2D: patients will initially receive 1.8 mg/kg BXQ-350 in combination with mFOLFOX7 and Bevacizumab. If safe (no MTD), dose of BXQ-350 will be increased to 2.4 mg/kg and 9 additional patients will be entered at this dose level. If safe, then this dose will be the RP2D and 21 additional patients will be enrolled, completing a 30-patient expansion cohort. Efficacy will then be evaluated for all patients entered at the RP2D. Primary objectives of the Phase 1b are to assess safety, identify RP2D, and assess preliminary efficacy of BXQ-350 in this combination. A secondary objective is to determine if BXQ-350 decreases CIPN. Design of the Phase 2, a double-blinded, placebo-controlled study: Eligible patients (up to 160 patients) will be randomized in a 1:1 fashion to receive either BXQ-350 or placebo with mFOLFOX7 + Bevacizumab. Primary and secondary objectives include efficacy, safety and CIPN incidence. Enrollment in the Phase 1b dose escalation portion is completed. After review of the safety results, the DSMB approved enrollment of the expansion cohort, with a planned 30 patients at the Phase 2 dose. Primary endpoints are Cumulative Oxaliplatin Dose, ORR and Safety. Secondary endpoints are OS, PFS, DCR, CIPN, PK/PD and biomarkers. Clinical trial information: NCT05322590 .
Details
- Title: Subtitle
- A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma
- Creators
- Tariq Arshad - Bexion PharmaceuticalsMichael Gazda - Bexion PharmaceuticalsGilles Tapolsky - Bexion PharmaceuticalsJim Beach - Bexion PharmaceuticalsDaniel Blake Flora - St. Elizabeth HealthcareReema Anil Patel - University of KentuckyFa Chyi Lee - University of California, IrvineDouglas B. Flora - St. Elizabeth HealthcareDavendra Sohal - University of CincinnatiSaima Sharif - University of IowaKi Young ChungJohn L. Villano - University of KentuckyVivek Sharma - James Graham Brown FoundationJulie Anne L. Gemmill - Stony Brook University HospitalAgustin Pimentel - University of MiamiNashat Y. Gabrail - Gabrail Cancer CenterDarryl Alan Outlaw - University of Alabama at BirminghamAri David Baron - Hematology Oncology AssociatesBrian C. Boulmay - Louisiana State University Health Sciences Center New OrleansBexion PIs
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.44(2_suppl)
- DOI
- 10.1200/JCO.2026.44.2_suppl.TPS273
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 01/10/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9985121498802771
Metrics
1 Record Views